Vir Biotechnology, Inc.
Vir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024. In the quarter to June 2026, revenue grew 19,582.5%, EPS grew 160.0% and free cash flow grew 200.5%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
Follow VIR
Vir Biotechnology, Inc. (VIR) EV/Sales
As of 16 October 2026, Vir Biotechnology, Inc. (VIR) trades at a EV/Sales of 3.7×. Over the past ten years it has ranged from −20.5× (November 2019) to 475× (June 2020); the current reading is higher than 56% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.3× | 7,352.72% |
| FY2024 | 0.1× | — |
| FY2023 | −1.5× | — |
| FY2022 | 0.6× | (87.22%) |
| FY2021 | 4.3× | (86.54%) |
| FY2020 | 32.0× | — |
| FY2019 | −1.0× | — |
| FY2018 | −18.2× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.9× | (69.88%) |
| Mar 2026 | 12.9× | 140.61% |
| Dec 2025 | 5.3× | (68.34%) |
| Sep 2025 | 16.9× | 8,969.32% |
| 27 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| BHVN Biohaven Ltd. compare | 1.6× |
| VIR Vir Biotechnology, Inc. | 3.7× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.3× |
| URGN Urogen Pharma compare | 9.7× |
| SEPN Septerna, Inc. compare | 12.7× |
| XNCR Xencor, Inc. compare | 13.4× |
| PVLA Palvella Therapeutics, Inc. compare | 35.6× |
| MESO Mesoblast Limited compare | 137× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)